POS1353 ASSOCIATION OF HEMATOLOGICAL COMPOSITE SCORES WITH RPDAI, RPDAM, AUTOANTIBODIES AND SPECIFIC MEDICATION REGIMENS IN PATIENTS WITH RELAPSING POLYCHONDRITIS

Ying Liang(BGI Group (China)), Yong Jiang(Sun Yat-sen University), Shaowei Xie(Shanghai Jiao Tong University), Lu Chen(National Clinical Research), Wei Zhu(Ministry of Education of the People's Republic of China), Xi Jia(Sun Yat-sen University)
Annals of the Rheumatic Diseases
June 1, 2025
10.1016/j.ard.2025.06.702
Cited by 0

Related Papers

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
|Annals of the Rheumatic Diseases|2011|412
Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases
|PLoS ONE|2012|196
Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53
|Nature Communications|2015|171
Metabolic Control by Heat Stress Determining Cell Fate to Ferroptosis for Effective Cancer Therapy
|ACS Nano|2021|169
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
|Annals of the Rheumatic Diseases|2013|168